Executive Order 14370
Increasing Medical Marijuana and Cannabidiol Research
Health Deregulation
Directs agencies to reduce barriers to medical marijuana and CBD research and to expedite the rescheduling process for marijuana.
Section by Section
What each section does, and how they differ.
Sec. 1 Purpose and Policy
Directs federal action to advance research into medical marijuana and cannabidiol products while streamlining regulatory pathways for patient access.
Sec. 2 Rescheduling Medical Marijuana and Improving Access to Cannabidiol Products
Directs the Attorney General to complete rescheduling of marijuana to Schedule III, and authorizes development of regulatory framework for hemp-derived cannabinoid products with research guidance on THC limits and CBD-to-THC ratios.
Sec. 3 General Provisions
Standard boilerplate: preserves existing agency authority, conditions the order on appropriations, and creates no enforceable private rights.
Related Executive Orders
Same subject matter
May -- December 2025